Ataxia is a wide variety of neurological disorders, characterized by a loss of balance and coordination in the body. It is caused by damage to various parts of the central nervous system, resulting in disordered motor movements, such as an unsteady and clumsily gait and the difficulty in coordinating voluntary movements associated with activities like walking, writing, brushing teeth, and talking. Generally, ataxia is categorized as either inherited, acquired, or symptomatic. Inherited ataxia is usually the result of genetic mutations, inherited from one’s parents, that disrupts the connections between some parts of the brain and parts of the body, or disrupts the functioning of the nervous system in some way. The most common type of inherited ataxia is spinocerebellar ataxia, an incurable progressive disorder with symptoms typically appearing in mid-late adulthood and, eventually, leading to mobility impairment. Acquired ataxia may be caused by a stroke, trauma, or serious infection. In such cases, the damage is confined to particular parts of the nervous system, resulting in impairments in motor control over particular regions of the body, such as the arms or legs. Similarly, symptomatic ataxia may also be caused by a disease, such as multiple sclerosis, or a side effect of certain medications. Ultimately, ataxia affects each individual differently and can range from mild to severe. Fortunately, there are treatments available such as physical and occupational therapy, medications, electrical stimulation, and even gene therapy.
Title : Perception and individuality in patient cases identifying the ongoing evolution of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ken Ware, NeuroPhysics Therapy Institute, Australia
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : Personalized and Precision Medicine (PPM), as a unique healthcare model through biodesign-driven biotech and biopharma, translational applications, and neurology-related biomarketing to secure human healthcare and biosafety
Sergey Victorovich Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Neuro sensorium
Luiz Moutinho, University of Suffolk, United Kingdom
Title : GBF1 inhibition reduces amyloid-beta levels in viable human postmortem Alzheimer's disease cortical explant and cortical organoid models
Sean J Miller, Yale School of Medicine, United States
Title : Traumatic Spinal Cord Injuries (tSCI) - Are the radiologically based “advances” in the management of the injured spine evidence-based?
W S El Masri, Keele University, United Kingdom